COLUMBUS, Ohio – April 14, 2022 – Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that Timothy J. Miller, Ph.D., CEO, President, and Co-Founder of Forge Biologics, and David Dismuke, Ph.D., Chief Technical Officer, will be presenting at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit virtually on Monday, April 25, 2022, at 1:30 p.m. Eastern Time.
The company presentation will be delivered via live webcast and may be accessed for 90 days by visiting Forge’s Events website at https://www.forgebiologics.com/news/#events.
About Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge has a 200,000 square foot facility in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com.
Media Inquiries
Marina Corleto – Forge Biologics
Senior Manager, Marketing and Communications
media@forgebiologics.com
Business Development
Magdalena Tyrpien – Forge Biologics
Senior Vice President, Head of Business Development
BD@forgebiologics.com
Client Development
John Maslowski, M.S. – Forge Biologics
Chief Commercial Officer
CD@forgebiologics.com
Investor Relations
Christina Perry – Forge Biologics
Senior Vice President, Finance and Investor Relations
Investors@forgebiologics.com